IFNG and glioblastoma: A separate study has also reported that effective CAR T cell antitumor activity of IL13Ra2-CAR T cells against mouse syngeneic glioblastoma (GBM) is significantly dependent on the activation of patient-derived endogenous T cells and monocyte/macrophages at the tumor site in an IFNγ-dependent manner (101).